Compliance to adjuvant therapy in breast cancer patients

C. Dittmer*, K. Roeder, F. Hoellen, D. Salehin, M. Thill, D. Fischer

*Corresponding author for this work
8 Citations (Scopus)


During recent years a continuous reduction of mortality from breast cancer has taken place in the Western countries. We wanted to verify whether the actual therapy for our own cases deviates from our recommendations, although the surgeon, radiotherapist and gynaecological oncologist are on the same premises. We sent out questionnaires to all newly diagnosed breast cancer patients in the last seven years regarding their adjuvant therapy. Comparing these answers to our own recommendation showed a very good compliance regarding chemotherapy and radiation therapy. Adjuvant endocrine therapy showed a very poor compliance with an adherence of 77%. Overall we can conclude that endocrine therapy causes many side-effects that seem to burden the patients. In combination with the duration of the therapy this causes a severe reduction in compliance and length of the therapy.

Original languageEnglish
JournalEuropean Journal of Gynaecological Oncology
Issue number3
Pages (from-to)280-282
Number of pages3
Publication statusPublished - 18.07.2011


Dive into the research topics of 'Compliance to adjuvant therapy in breast cancer patients'. Together they form a unique fingerprint.

Cite this